Answer
Patients receiving Hemgenix (etranacogene dezaparvovec) should be closely monitored for infusion reactions throughout the infusion and for at least 3 hours after it ends.
Sources for this answer
- HemgenixCSL Behring UK Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 6Document updated
Sources checked